Correction: Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
Format: | Article |
---|---|
Language: | English |
Published: |
BMJ Publishing Group
2023-12-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/12/e006982corr1.full |
Similar Items
-
Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
by: Hong Sun, et al.
Published: (2023-06-01) -
Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review
by: Kuan-Chang Lai, et al.
Published: (2022-08-01) -
Correction: Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
Published: (2023-11-01) -
Correction: Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
Published: (2022-09-01) -
Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review
by: Lei Pan, et al.
Published: (2023-01-01)